Melanoma, Malignant Terminated Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Malignant Melanoma / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0107071 (Melanoma, Malignant)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01557114Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant MelanomaTreatment